SWS Partners Cuts Stock Holdings in Guardant Health, Inc. $GH

Key Points

• SWS Partners reduced its stake in Guardant Health by 11.2%, now holding 93,077 shares valued at approximately $4.84 million.
• Several large investors, including Driehaus Capital and Invesco, have increased their positions in Guardant Health, indicating strong interest in the stock.
• Analysts have given Guardant Health a composite rating of "Buy" with a consensus price target of $65.25, reflecting positive sentiment surrounding the company's future performance.

SWS Partners lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 11.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,077 shares of the company's stock after selling 11,740 shares during the period. Guardant Health makes up approximately 1.3% of SWS Partners' portfolio, making the stock its 18th biggest holding. SWS Partners owned approximately 0.08% of Guardant Health worth $4,844,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of GH. Driehaus Capital Management LLC purchased a new position in Guardant Health during the first quarter worth approximately $82,349,000. Invesco Ltd. raised its stake in Guardant Health by 100.9% during the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company's stock worth $119,053,000 after purchasing an additional 1,403,670 shares during the period. Iron Triangle Partners LP purchased a new position in Guardant Health during the first quarter worth approximately $25,597,000. Adage Capital Partners GP L.L.C. raised its stake in Guardant Health by 202.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 846,749 shares of the company's stock worth $36,072,000 after purchasing an additional 566,949 shares during the period. Finally, Emerald Advisers LLC purchased a new position in Guardant Health during the first quarter worth approximately $22,639,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Analysts Set New Price Targets

GH has been the subject of several recent research reports. Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research report on Monday, July 14th. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $60.00 to $70.00 and gave the stock an "overweight" rating in a research report on Thursday. Wells Fargo & Company initiated coverage on shares of Guardant Health in a research report on Monday, September 22nd. They issued an "overweight" rating and a $72.00 price objective for the company. Scotiabank increased their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research report on Thursday, July 31st. Finally, Raymond James Financial increased their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating and twenty-two have assigned a Buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $65.25.

Guardant Health Trading Down 0.2%

GH opened at $60.03 on Monday. The company has a fifty day simple moving average of $55.61 and a 200 day simple moving average of $48.93. The firm has a market cap of $7.49 billion, a price-to-earnings ratio of -17.92 and a beta of 1.45. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $68.00.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to analyst estimates of $211.19 million. Guardant Health's revenue for the quarter was up 31.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. On average, analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,971,830 shares of the company's stock, valued at $100,326,710.40. This trade represents a 4.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the firm's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the transaction, the director directly owned 851 shares of the company's stock, valued at approximately $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 402,691 shares of company stock valued at $23,069,965. Corporate insiders own 6.10% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.